Choroidal Nevus (Eye Freckle): What It Means and When to Worry

Many people first hear the words "choroidal nevus" after a routine eye test, when the optometrist or ophthalmologist notices a flat grey-brown spot at the back of the eye. It is natural to worry when the word "melanoma" comes up in the same conversation. The reassuring news is that the great majority of these spots stay harmless for life. The important task is to recognize the small number that need closer attention.

This page explains what a choroidal nevus is, which features make doctors more cautious, how the lesion is measured and monitored, and when it is sensible to ask an ocular oncologist for an opinion.

What is a choroidal nevus?

The choroid is the blood-rich layer that lies between the retina (the light-sensitive film of the eye) and the white outer wall (sclera). Like the skin, it contains pigment cells called melanocytes. When these cells gather into a small, well-defined cluster, the result is a nevus — the same kind of benign lesion as a mole or freckle on the skin, but hidden inside the eye.

A typical choroidal nevus is:

• flat or only slightly raised (usually under 2 mm thick);
• grey-brown, although some are pale or unpigmented;
• well demarcated, sometimes with small yellow deposits called drusen on its surface or a pale halo around it — both reassuring signs of a long-standing lesion.

You cannot see or feel a nevus yourself. It is found only when the back of the eye is examined through a dilated pupil or photographed with a retinal camera.

How common is it, and can it turn into cancer?

Choroidal nevi are among the most frequent findings in adult eye examinations. Studies estimate that about 4.6–7.9% of adults of European descent have at least one; they are less common in people of African and Asian ancestry.

The chance that an individual nevus turns into a choroidal melanoma is very small. A widely quoted population estimate is about 1 in 8,845 nevi per year, which adds up to less than 1% over a lifetime. Specialist centers report higher figures — for example, in a Wills Eye Hospital cohort of more than 2,300 nevi followed over time, about 6% had transformed after 5 years — but those patients were referred precisely because their lesions already looked suspicious, so the numbers do not apply to an ordinary freckle found on a routine check.

Does a choroidal nevus cause symptoms?

Usually not. Symptoms are uncommon and deserve prompt examination because they can signal fluid or growth. They include:

• blurred or distorted central vision;
• flashes of light, new floaters, or a shadow in part of the visual field;
• a noticeable change in vision in one eye.

Occasionally a benign nevus causes a small amount of fluid under the retina or abnormal new blood vessels (choroidal neovascularization). These complications are treatable, most often with injections into the eye.

How do doctors tell a nevus from a small melanoma?

A small melanoma can look very similar to a nevus. Instead of relying on appearance alone, specialists measure a set of risk features with several imaging methods (this is called multimodal imaging) and add them up.

The TFSOM-DIM risk factors

A widely used checklist in ocular oncology comes from the same specialist-center series quoted above: the study, published in 2019, analyzed 3,806 choroidal nevi. Its mnemonic — "To Find Small Ocular Melanoma Doing IMaging" — lists six features:

The more features a lesion has, the higher its chance of growing into melanoma within 5 years. In that series, lesions with no risk factors transformed in about 1% of cases, those with one factor in about 11%, two factors about 22%, three about 34%, and four or more in about half.

The MOLES score

A simpler system called MOLES, developed by Professor Bertil Damato for optometrists and general ophthalmologists, scores five features from 0 to 2: Mushroom shape, Orange pigment, Large size, Enlargement (documented growth) and Subretinal fluid. A total of 0 suggests a common nevus, 1 a low-risk nevus and 2 a high-risk nevus that needs imaging and follow-up; 3 or more suggests probable melanoma and urgent referral to an ocular oncologist. In validation studies from London and Germany, a score of 3 or more identified all melanomas in the study groups while correctly classifying about 96% of benign nevi.

Which tests are used?

Each test adds a different piece of information. Together they form the baseline against which future examinations are compared.

• Wide-field color fundus photography documents the size, color and margins of the lesion. Photographs taken months apart are the most reliable way to detect growth.
• Ultrasound (A- and B-scan) measures thickness to a fraction of a millimeter and shows whether the lesion is "acoustically hollow", a feature more typical of melanoma.
• Optical coherence tomography (OCT) shows fine fluid under the retina and changes in the photoreceptor layer that are invisible on a normal examination.
• Fundus autofluorescence (FAF) highlights orange pigment (lipofuscin), which glows brightly on this scan.
• Fluorescein or indocyanine green angiography is used selectively, for example when abnormal blood vessels or other tumor types need to be excluded.

A biopsy is rarely needed for a nevus. It is reserved for lesions where the diagnosis remains uncertain and the result would change treatment. You can read more about each test on our page on how eye tumors are diagnosed.

How often should a choroidal nevus be checked?

Follow-up depends on the risk profile, and the schedule is always individual. Typical intervals used by specialists are:

Bring previous photographs and scan reports to every visit if you change doctors or countries. A single image from years ago can be the key to deciding that a lesion has been stable all along.

What if the lesion is growing or looks like a small melanoma?

Documented growth is the single most important warning sign. When an ocular oncologist concludes that a lesion is, or is very likely to be, a small melanoma, the options today are more eye-friendly than ever:

• Close observation may still be appropriate for some borderline ("indeterminate") lesions, with repeat imaging after a short interval.
• Photodynamic therapy or transpupillary thermotherapy can treat selected small, flat tumors located away from the optic nerve.
• Plaque brachytherapy — a small radioactive disc placed temporarily on the outside of the eye — is the most common eye-preserving treatment for melanomas that need radiation.
• Clinical trials are testing new approaches for small melanomas and indeterminate lesions. The phase 3 CoMpass trial of bel-sar (belzupacap sarotalocan), a light-activated drug, completed enrollment of 108 patients in June 2026; results are expected in the second half of 2027. As of September 2026 bel-sar is an investigational treatment available only within trials.

The details of each option are covered on the uveal melanoma page.

Getting a specialist opinion in Antalya

Most nevi can be followed safely by a general ophthalmologist or optometrist. An ocular oncology opinion is worth considering when a lesion has two or more risk features, has grown, is very close to the optic nerve or the center of vision, or when you simply want a definitive answer.

Prof. Türkoğlu reviews the complete imaging record, repeats measurements where needed and explains the findings in plain language, together with a recommended follow-up schedule. Patients who live abroad can start with a remote second opinion by sending their photographs, ultrasound and OCT reports; if an examination in Antalya is advisable, the visit is planned in advance so that you know which tests are needed and how long to allow.